Ciprofloxacin In Dextroseciprofloxacin

According to the FDA label: Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in…

70,303 adverse event reports submitted to the FDA (1997–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Ciprofloxacin In Dextrose in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Ciprofloxacin In Dextrose adverse event reports by reporter sex
SexReports
Female35,392
Male28,512
Unknown275

By Age Group

View age group data as a table
Ciprofloxacin In Dextrose adverse event reports by reporter age group
Age groupReports
0-172,577
18-346,650
35-498,771
50-6413,912
65-7410,952
75+9,506

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Ciprofloxacin In Dextrose. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Ciprofloxacin In Dextrose adverse event reports by reported outcome
OutcomeReports
Other Serious41,091
Hospitalization29,350
Non-Serious8,193
Death7,794
Disability5,238
Life-Threatening4,945

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Ciprofloxacin In Dextrose. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Ciprofloxacin In Dextrose adverse event reports by year
YearReports
19971
19992
20011
20021
20031
2004648
2005668
2006803
2007907
2008956
20091,190
20101,480
20112,563
20122,355
20132,101
20142,273
20153,125
20164,053
20173,979
20186,479
20197,779
20205,677
20215,400
20224,311
20234,662
20244,389
20253,768
2026 (partial)731

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Ciprofloxacin In Dextrose

In FDA adverse event reports that mention Ciprofloxacin In Dextrose, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026